Hormonal
Semaglutide (subcutaneous 1 mg/week and oral 14 mg/day) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with subcutaneous administration showing superior efficacy compared to other GLP-1 receptor agonists.
Semaglutide is a highly effective GLP-1 receptor agonist for lowering blood sugar (HbA1c) and reducing body weight in type 2 diabetes patients. It is available in both weekly injections (1 mg) and daily oral tablets (14 mg), with the injection showing slightly greater efficacy. For obese non-diabetics, a higher injection dose (2.4 mg) leads to significant weight loss (~15%). While nausea is a common side effect, it is usually manageable. Patients with pre-existing eye disease (retinopathy) should use it cautiously due to a potential increased risk of retinal complications.
Semaglutide s.c. settimanale, al dosaggio massimale di 1 mg, riduceva il peso corporeo di circa 6,5 Kg, mentre per la formulazione orale la riduzione era di circa 4,5 Kg... Semaglutide s.c. è il GLP-1 RA con maggiore impatto sulla riduzione di HbA1c e peso corporeo.
Why this rating
Based on multiple randomized controlled trials (SUSTAIN 6, PIONEER 6, STEP 1) and comparative meta-analyses cited.
Source
Semaglutide
Agostino Milluzzo et al. · L Endocrinologo · 2022
DOI 10.1007/s40619-022-01061-0
More from this paper
- Semaglutide reduces cardiovascular risk (MACE) and improves lipid profiles and blood pressure in patients with type 2 diabetes, independent of weight loss.Good
- Semaglutide use in patients with pre-existing retinopathy is associated with an increased risk of retinal complications, likely due to rapid glycemic improvement, requiring cautious use.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →